BiotechTube
Bonesupport Holding AB

Bonesupport Holding AB

BONEX.STPre-clinical
100-250 employeesbonesupport.com

Bonesupport Holding AB is a commercial-stage orthobiologics company focused on improving outcomes in bone infection and complex trauma through its proprietary CERAMENT® technology platform. The company's core innovation is an injectable, osteoconductive calcium sulfate/hydroxyapatite bone graft that can be loaded with antibiotics for local delivery. With regulatory approvals in key markets and a growing commercial footprint, Bonesupport aims to become a leader in the management of bone infections and complex fractures, leveraging clinical data demonstrating reduced infection recurrence and improved healing.

Market Cap
$1.3B
-44.6% period
Pipeline
—
Patents
—
Publications
3
indexed

BONEX.ST · Stock Price

USD 178.50143.70 (-44.60%)

Historical price data

AI Company Overview

Bonesupport Holding AB is a commercial-stage orthobiologics company focused on improving outcomes in bone infection and complex trauma through its proprietary CERAMENT® technology platform. The company's core innovation is an injectable, osteoconductive calcium sulfate/hydroxyapatite bone graft that can be loaded with antibiotics for local delivery. With regulatory approvals in key markets and a growing commercial footprint, Bonesupport aims to become a leader in the management of bone infections and complex fractures, leveraging clinical data demonstrating reduced infection recurrence and improved healing.

OrthopedicsTraumaInfectious Disease

Technology Platform

CERAMENT® platform: an injectable, osteoconductive, and fully resorbable synthetic bone graft substitute composed of calcium sulfate/hydroxyapatite, engineered for local elution of antibiotics (e.g., gentamicin, vancomycin) directly at the site of bone infection or defect.

Funding History

4
Total raised:$60M
IPO$40MJun 16, 2017
Series B$15MJun 15, 2006
Series A$5MJun 15, 2003
SeedUndisclosedJun 15, 1999

Opportunities

Significant growth opportunity lies in the full commercialization of CERAMENT® in the large U.S.
market, particularly in trauma and infected revision arthroplasty.
Further label expansions into adjacent indications like fragility fracture augmentation and the U.S.
approval of CERAMENT® V could drive long-term revenue streams.
Geographic expansion into Asia-Pacific markets represents another potential growth vector.

Risk Factors

Key risks include the challenge of commercial execution and achieving surgeon adoption in the highly competitive U.S.
orthopedics market, dependence on favorable reimbursement decisions from payers, and the potential for clinical or regulatory setbacks in ongoing development programs.
The company also faces competition from large, well-established medtech companies with broader portfolios.

Competitive Landscape

Bonesupport competes with large medtech players like Stryker and Zimmer Biomet, as well as specialized orthobiologics companies. Its main differentiation is CERAMENT®'s injectability and full resorbability, which avoids the need for a second removal surgery required by traditional non-resorbable antibiotic beads. Clinical data demonstrating reduced infection recurrence is a core competitive asset.